Related Experiment Videos
C1q: a multifunctional ligand for a new immunoadsorption treatment
Insights
C1q immunoadsorption effectively removed waste materials in a clinical trial for systemic lupus erythematosus (SLE) patients. This innovative treatment shows promise for managing autoimmune diseases by targeting C1q, a key immune protein.
Area of Science:
- Immunology
- Complement System
- Autoimmune Diseases
Background:
- C1q is a conserved protein crucial for innate and adaptive immunity.
- It activates the classical complement pathway, aiding in the clearance of pathogens, apoptotic cells, and immune complexes by the mononuclear phagocyte system.
- The collagen-like region of C1q is a target for autoantibodies, implicated in autoimmune disease pathogenesis.
Purpose of the Study:
- To investigate the potential of C1q as a target for removing circulating waste materials.
- To evaluate the safety and efficacy of a novel C1q immunoadsorbent in a clinical setting.
Main Methods:
- Development of a C1q immunoadsorbent.
- Clinical trial involving 8 patients with systemic lupus erythematosus (SLE).
Main Results:
- C1q immunoadsorption demonstrated safety and compatibility in SLE patients.
- Preliminary results indicate effectiveness in treating SLE.
Conclusions:
- C1q immunoadsorption is a safe, compatible, and effective therapeutic approach for SLE patients.
- C1q holds promise for extracting circulating waste materials and managing autoimmune conditions.
Abstract:
C1q is a highly conserved protein with multiple functions involved in innate and adaptive immunity. It plays an important role in the activation of the classical pathway of the complement system to mediate the scavenging of infectious agents, apoptotic products, and immune complexes by the mononuclear phagocyte system (MPS). Exhibiting this function, C1q is able to bind various molecules (complexed IgG, IgM, fibrinogen, fibronectin, lipopolysaccharides, DNA, C-reactive protein [CRP], and viral proteins). Moreover, the collagen-like region of C1q is a target of autoantibodies. Immune complexes and anti-C1q autoantibodies are known to be involved in the pathogenesis of autoimmune diseases. Therefore, C1q is a promising candidate to extract waste material from the circulation. Following the development of the C1q immunoadsorbent, 8 patients with systemic lupus erythematosus (SLE) were treated in a first clinical trial. These preliminary results indicate that C1q immunoadsorption is a safe, compatible, and effective treatment for these patients.